A practical framework categorizes TKIs into three classes to guide adjuvant use. Class 1 (e.g., osimertinib, alectinib) has high efficacy and low toxicity, making extrapolation easy. Class 2 (e.g., BRAF/MET inhibitors) has moderate efficacy and higher toxicity, requiring trials. Class 3 (e.g., KRAS inhibitors) has lower activity and needs trials.

The standard of care for newly diagnosed EGFR-mutated non-small cell lung cancer has shifted from osimertinib monotherapy to combination regimens. Experts agree that combinations (e.g., osimertinib/chemo) should be the default choice, with monotherapy now reserved for cases with significant tolerability concerns.

When treating EGFR-mutated NSCLC that has progressed on osimertinib, leading oncologists advocate for continuing the TKI even when adding a new agent like datopotamab deruxtecan. This off-label practice is based on strong biological rationale and consistent trial data showing benefit from maintaining EGFR inhibition.

The FLORA two study's overall survival benefit was so compelling that clinicians should now default to osimertinib plus chemotherapy for most first-line EGFR-mutant NSCLC patients, only opting out for specific reasons like comorbidities or patient preference.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

Despite initial benefits, fewer than 10% of EGFR-mutated NSCLC patients on osimertinib monotherapy survive five years. A significant portion (25-40%) never even receive a second-line treatment, highlighting the limitations of this once-standard approach.

For patients with atypical (non-exon 19/21) EGFR mutations, the treatment landscape has expanded. Recent ASCO guideline updates now recommend three different first-line options—afatinib, osimertinib, and amivantamab with lazertinib—signaling a move away from a one-size-fits-all approach for this diverse patient subgroup.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.